Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
1. Novo Nordisk's Wegovy shows superior cardiovascular safety compared to LLY's tirzepatide. 2. Wegovy resulted in 57% greater risk reduction for major cardiovascular events. 3. Higher incidence of cardiovascular events was observed with LLY's tirzepatide treatment. 4. Novo Nordisk plans to seek U.S. approval for a high-dose Wegovy version. 5. NVO stock rose 7.63% on positive study results.